拉沙热疫苗研究进展
|
摘要
拉沙热是由拉沙病毒(Lassa virus,LASV)引起的一种急性传染病,主要由啮齿类动物传给人。西非是拉沙热最主要的流行区,该地区每年有几十万人患病,数千例死亡。由于LASV的高致病性,被列为潜在生物战剂,当前无获批的拉沙热疫苗。研究表明传统的灭活疫苗免疫保护效果不理想,LASV基因重组的复制增殖型病毒载体疫苗、复制缺陷型病毒载体疫苗和DNA疫苗等新型疫苗显示较好的发展前景。但是这几种新型疫苗仍处于临床预试验阶段或临床试验阶段。
Lassa fever is an acute viral disease caused by Lassa virus(LASV). The virus is mainly transmitted to humans by a rodent reservoir, Mastomys natalensis. The infection is endemic in West African countries, resulting in hundreds of thousands of cases annually, and causing approximately thousands of deaths each year. Due to its high pathogenicity, LASV is recognized as a potential agent of bio-warfare. Currently, there are no licensed vaccines for Lassa fever. Studies have shown that the vaccine prepared by in-activated LASV is not ideal for eliciting a protective immune response. Recently, several promising vaccine candidates against Lassa fever have been developed, such as replication-competent virus-vectored vaccines, replication-deficient virus-vectored vaccines and DNA vaccines. However, these novel types of vaccine candidates against Lassa fever remain to be pre-clinically and/or clinically evaluated.
Lassa fever is an acute viral disease caused by Lassa virus(LASV). The virus is mainly transmitted to humans by a rodent reservoir, Mastomys natalensis. The infection is endemic in West African countries, resulting in hundreds of thousands of cases annually, and causing approximately thousands of deaths each year. Due to its high pathogenicity, LASV is recognized as a potential agent of bio-warfare. Currently, there are no licensed vaccines for Lassa fever. Studies have shown that the vaccine prepared by in-activated LASV is not ideal for eliciting a protective immune response. Recently, several promising vaccine candidates against Lassa fever have been developed, such as replication-competent virus-vectored vaccines, replication-deficient virus-vectored vaccines and DNA vaccines. However, these novel types of vaccine candidates against Lassa fever remain to be pre-clinically and/or clinically evaluated.
引文
[1]中华人民共和国农业部.中华人民共和国兽用生物制品质量标准[M].北京:中国农业科技出版社,2001:316-317.
[2]Mc Cormick JB,Webb PA,Krebs JW,et al.A prospective study of the epidemiology and ecology of Lassa fever[J].J Infect Dis,1987,155(3):437-444.
[3]Geisbert TW,Jones S,Fritz EA,et al.Development of a new vaccine for the prevention of Lassa fever[J].PLo S Med,2005,2(6):e1831.
[4]Kiley MP,Lange JV,Johnson KM.Protection of rhesus monkeys from Lassa virus by immunisation with closely related Arenavirus[J].Lancet,1979,2(8145):738.
[5]Fisher-Hoch SP,Hutwagner L,Brown B,et al.Effective vaccine for Lassa fever[J].J Virol,2000,74(15):6777-6783.
[6]Fisher-Hoch SP,Mc Cormick JB,Auperin D,et al.Protection of rhesus monkeys from fatal Lassa fever by vaccination with a recombinant vaccinia virus containing the Lassa virus glycoprotein gene[J].Proc Natl Acad Sci U S A,1989,86(1):317-321.
[7]Zapata JC,Goicochea M,Nadai Y,et al.Genetic variation in vitro and in vivo of an attenuated Lassa vaccine candidate[J].J Virol,2014,88(6):3058-3066.
[8]Mitchell SW,Mc Cormick JB.Physicochemical inactivation of Lassa,Ebola,and Marburg viruses and effect on clinical laboratory analyses[J].J Clin Microbiol,1984,20(20):486-489.
[9]KrasnianskiǐVP,Potryvaeva NV,Borisevich IV,et al.A trial to produce an inactivated Lassa fever vaccine[J].Vopr Virusol,1993,38(6):276-279.
[10]Morelli AB,Becher D,Koernig S,et al.ISCOMATRIX:a novel adjuvant for use in prophylactic and therapeutic vaccines against infectious diseases[J].J Med Microbiol,2012,61(Pt 7):935-943.
[11]Mc Clain,DJ,Summers PL,Harrison SA,et al.Clinical evaluation of a vaccinia-vectored Hantaan virus vaccine[J].J Med Virol,2000,60(1):77-85.
[12]Bredenbeek PJ,Molenkamp R,Spaan WJ,et al.A recombinant Yellow Fever 17D vaccine expressing Lassa virus glycoproteins[J].Virology,2006,345(2):299-304.
[13]Jiang X,Dalebout TJ,Bredenbeek PJ,et al.Yellow fever 17D-vectored vaccines expressing Lassa virus GP1 and GP2 glycoproteins provide protection against fatal disease in guinea pigs[J].Vaccine,2011,29(6):1248-1257.
[14]Garbutt M,Liebscher R,Wahl-Jensen V,et al.Properties of replication-competent vesicular stomatitis virus vectors expressing glycoproteins of filoviruses and arenaviruses[J].J Virol,2004,78(10):5458-5465.
[15]Jahrling PB,Hesse RA,Eddy GA,et al.Lassa virus infection of rhesus monkeys:pathogenesis and treatment with ribavirin[J].J Infect Dis,1980,141(5):580-589.
[16]Pushko P,Geisbert J,Parker M,et al.Individual and bivalent vaccines based on alphavirus replicons protect guinea pigs against infection with Lassa and Ebola viruses[J].J Virol,2001,75(23):11677-11685.
[17]Branco LM,Grove JN,Geske FJ,et al.Lassa virus-like particles displaying all major immunological determinants as a vaccine candidate for Lassa hemorrhagic fever[J].Virol J,2010,7:279.
[18]Rodriguez-Carreno MP,Nelson MS,Botten J,et al.Evaluating the immunogenicity and protective efficacy of a DNA vaccine encoding Lassa virus nucleoprotein[J].Virology,2005,335(1):87-98.
[19]Grant-Klein RJ,Altamura LA,Schmaljohn CS.Progress in recombinant DNA-derived vaccines for Lassa virus and filoviruses[J].Virus Res,2011,162(1-2):148-161.
[20]Fisher-Hoch SP,Mc Cormick JB.Towards a human Lassa fever vaccine[J].Rev Med Virol,2001,11(5):331-341.
[21]Bowen MD,Rollin PE,Ksiazek TG,et al.Genetic diversity among Lassa virus strains[J].J Virol,2000,74(15):6992-7004.
[22]Baize S,Marianneau P,Loth P,et al.Early and strong immune responses are associated with control of viral replication and recovery in lassa virus-infected cynomolgus monkeys[J].J Virol,2009,83(11):5890-5903.
[2]Mc Cormick JB,Webb PA,Krebs JW,et al.A prospective study of the epidemiology and ecology of Lassa fever[J].J Infect Dis,1987,155(3):437-444.
[3]Geisbert TW,Jones S,Fritz EA,et al.Development of a new vaccine for the prevention of Lassa fever[J].PLo S Med,2005,2(6):e1831.
[4]Kiley MP,Lange JV,Johnson KM.Protection of rhesus monkeys from Lassa virus by immunisation with closely related Arenavirus[J].Lancet,1979,2(8145):738.
[5]Fisher-Hoch SP,Hutwagner L,Brown B,et al.Effective vaccine for Lassa fever[J].J Virol,2000,74(15):6777-6783.
[6]Fisher-Hoch SP,Mc Cormick JB,Auperin D,et al.Protection of rhesus monkeys from fatal Lassa fever by vaccination with a recombinant vaccinia virus containing the Lassa virus glycoprotein gene[J].Proc Natl Acad Sci U S A,1989,86(1):317-321.
[7]Zapata JC,Goicochea M,Nadai Y,et al.Genetic variation in vitro and in vivo of an attenuated Lassa vaccine candidate[J].J Virol,2014,88(6):3058-3066.
[8]Mitchell SW,Mc Cormick JB.Physicochemical inactivation of Lassa,Ebola,and Marburg viruses and effect on clinical laboratory analyses[J].J Clin Microbiol,1984,20(20):486-489.
[9]KrasnianskiǐVP,Potryvaeva NV,Borisevich IV,et al.A trial to produce an inactivated Lassa fever vaccine[J].Vopr Virusol,1993,38(6):276-279.
[10]Morelli AB,Becher D,Koernig S,et al.ISCOMATRIX:a novel adjuvant for use in prophylactic and therapeutic vaccines against infectious diseases[J].J Med Microbiol,2012,61(Pt 7):935-943.
[11]Mc Clain,DJ,Summers PL,Harrison SA,et al.Clinical evaluation of a vaccinia-vectored Hantaan virus vaccine[J].J Med Virol,2000,60(1):77-85.
[12]Bredenbeek PJ,Molenkamp R,Spaan WJ,et al.A recombinant Yellow Fever 17D vaccine expressing Lassa virus glycoproteins[J].Virology,2006,345(2):299-304.
[13]Jiang X,Dalebout TJ,Bredenbeek PJ,et al.Yellow fever 17D-vectored vaccines expressing Lassa virus GP1 and GP2 glycoproteins provide protection against fatal disease in guinea pigs[J].Vaccine,2011,29(6):1248-1257.
[14]Garbutt M,Liebscher R,Wahl-Jensen V,et al.Properties of replication-competent vesicular stomatitis virus vectors expressing glycoproteins of filoviruses and arenaviruses[J].J Virol,2004,78(10):5458-5465.
[15]Jahrling PB,Hesse RA,Eddy GA,et al.Lassa virus infection of rhesus monkeys:pathogenesis and treatment with ribavirin[J].J Infect Dis,1980,141(5):580-589.
[16]Pushko P,Geisbert J,Parker M,et al.Individual and bivalent vaccines based on alphavirus replicons protect guinea pigs against infection with Lassa and Ebola viruses[J].J Virol,2001,75(23):11677-11685.
[17]Branco LM,Grove JN,Geske FJ,et al.Lassa virus-like particles displaying all major immunological determinants as a vaccine candidate for Lassa hemorrhagic fever[J].Virol J,2010,7:279.
[18]Rodriguez-Carreno MP,Nelson MS,Botten J,et al.Evaluating the immunogenicity and protective efficacy of a DNA vaccine encoding Lassa virus nucleoprotein[J].Virology,2005,335(1):87-98.
[19]Grant-Klein RJ,Altamura LA,Schmaljohn CS.Progress in recombinant DNA-derived vaccines for Lassa virus and filoviruses[J].Virus Res,2011,162(1-2):148-161.
[20]Fisher-Hoch SP,Mc Cormick JB.Towards a human Lassa fever vaccine[J].Rev Med Virol,2001,11(5):331-341.
[21]Bowen MD,Rollin PE,Ksiazek TG,et al.Genetic diversity among Lassa virus strains[J].J Virol,2000,74(15):6992-7004.
[22]Baize S,Marianneau P,Loth P,et al.Early and strong immune responses are associated with control of viral replication and recovery in lassa virus-infected cynomolgus monkeys[J].J Virol,2009,83(11):5890-5903.